Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
News|Articles|June 6, 2025
Pulmonology Month in Review: May 2025
Author(s)Victoria Johnson
Fact checked by: Abigail Brooks, MA
Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.
Advertisement
Advertisement
In May, the field of pulmonology witnessed significant advancements in the management of chronic respiratory diseases, highlighted by new clinical trial data presented at the American Thoracic Society (ATS) 2025 International Conference. These developments spanned a range of conditions, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary sarcoidosis, offering promising insights into emerging therapies and treatment strategies.
Related to this article
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Advertisement
Advertisement